Special Issue "Theranostic Drug Delivery: Prospects and Problems"
Deadline for manuscript submissions: 31 May 2021.
Interests: nanoBiotechnology; drug delivery; pharmaceutics; molecular biology; liposomes; drug targeting; cancer; pharmaceutical nanotechnology
Theranostic drug delivery exploits the combined properties of diagnosis and therapy and as such can benefit the development of targeted drug delivery systems and modern personalized medicine. The theranostic approach is used to design and formulate biocompatible and smart protocols for controlled, stimuli-responsive gene or drug delivery for various applications. It is expected that the success of theranostics will depend on multidisciplinary efforts, combined to expedite our understanding of host responses to customized theranostic agents and formulating individualized therapies. This Special Issue aims to provide an up-to-date collection of original research articles and review papers on the development of novel targeted drug delivery systems for the encapsulation and delivery of chemotherapeutic reagents, DNA- and RNA-based molecules, peptides, and other bioactive compounds. The themed issue will encompass significant efforts aimed at using biological language to discern between “friends” and “foes” in the context of theranostics for accurate clinical applications.
Prof. M. R. Mozafari
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- controlled release
- drug carrier
- drug delivery
- drug targeting
- personalized medicine